Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Clinical trial NCT05102721 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05102721
- Sponsor
- Vaccinex Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-10
- Primary completion
- 2028-12-31
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.